Policy & Regulation
BioArctic and Mesenkia sign research collaboration for glioblastoma antibody project
19 August 2026 - Swedish biopharma company BioArctic AB (STO: BIOA-B), which develops treatments for neurodegenerative diseases, said on Wednesday it has entered a research collaboration with Mesenkia...
Tolerance Bio licenses clinical-stage IL-7 therapy from NeoImmuneTech
19 August 2026 - Tolerance Bio Inc, a biotechnology company focused on preserving, regenerating and modulating thymic function to address immune diseases and extend healthspan, announced on Wednesday ...
Merck and Moderna report positive Phase 3 melanoma trial results
19 August 2026 - US pharmaceutical company Merck & Co Inc (NYSE:MRK), known as MSD outside the US and Canada, and biotechnology company Moderna Inc (NASDAQ:MRNA) announced on Wednesday that the Ph...
Scancell announces UK authorisation for Phase 3 melanoma trial
19 August 2026 - Immuno-oncology company Scancell Holdings plc (AIM: SCLP) announced on Wednesday that it has received Clinical Trial Authorization from the UK Medicines and Healthcare Products Regula...
Initiator Pharma secures two European patents for pudafensine
19 August 2026 - Danish clinical-stage pharmaceutical company Initiator Pharma A/S (FN STO:INIT) announced on Wednesday that it has secured two new European patents for its lead drug candidate pudafen...
Resivant Medical reports first patient cases with Cutiva PLUS Skin Closure System
19 August 2026 - Resivant Medical announced on Tuesday the first patient uses of its Cutiva PLUS Skin Closure System, marking the first use of its proprietary Cutiva siliconised adhesive platform.This...